Acadia Pharmaceuticals (ACAD) Interest Coverage Ratio (2011 - 2026)
Acadia Pharmaceuticals (ACAD) posted quarterly Interest Coverage Ratio of 0.78 for Q1 2026, down 358.82% year-over-year from 0.3 in Q1 2025, and down 114.33% quarter-over-quarter from 5.45 in Q4 2025.
Acadia Pharmaceuticals (ACAD) Interest Coverage Ratio (2011 - 2026) Analysis & Trends
Acadia Pharmaceuticals' Interest Coverage Ratio history runs 16 years deep, the most recent figure standing at 0.78 for Q1 2026.
- In Q1 2026, Interest Coverage Ratio fell 358.82% year-over-year to 0.78; the TTM figure through Mar 2026 stood at 13.68 (up 272.57% YoY), while the FY2025 annual figure was 1.32, down 87.9% from the prior year.
- Interest Coverage Ratio for Q1 2026 stood at 0.78, down from 5.45 in the prior quarter.
- The five-year high for Interest Coverage Ratio was 59.64 in Q4 2024, with the low at 19.51 in Q4 2022.
- The 5-year median for Interest Coverage Ratio is 0.3 (2025), against an average of 3.33.
- The sharpest annual moves came in 2022 and 2024: Interest Coverage Ratio slumped 1697.47% in 2022, then surged 6853.33% in 2024.
- Acadia Pharmaceuticals' Interest Coverage Ratio stood at 19.51 in 2022, then jumped by 174.82% to 14.6 in 2023, then soared by 308.56% to 59.64 in 2024, then slumped by 90.87% to 5.45 in 2025, then sank by 114.33% to 0.78 in 2026.
- Business Quant data shows ACAD's Interest Coverage Ratio at 0.78 in Q1 2026, 5.45 in Q4 2025, and 3.13 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Acadia Pharmaceuticals | 4.86 Bn | 3.90 Bn | 279.64 Mn | 0.41 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.41 |
| Mar 31, 2026 | -0.78 |
| Dec 31, 2025 | 5.45 |
| Sep 30, 2025 | 3.13 |
| Jun 30, 2025 | 2.89 |
| Mar 31, 2025 | 0.30 |
| Dec 31, 2024 | 59.64 |
| Sep 30, 2024 | 3.90 |
| Jun 30, 2024 | 3.06 |
| Mar 31, 2024 | 1.53 |
| Dec 31, 2023 | 14.60 |
| Sep 30, 2023 | -0.87 |
| Jun 30, 2023 | 0.04 |
| Mar 31, 2023 | -0.75 |
| Dec 31, 2022 | -19.51 |
| Sep 30, 2022 | -3.44 |
| Jun 30, 2022 | -3.85 |
| Mar 31, 2022 | -8.79 |
| Dec 31, 2021 | -23.75 |
| Sep 30, 2021 | -0.19 |